Egypt’s pharmaceutical manufacturing sector is preparing for a new expansion phase in 2026, supported by significant private-sector investments aimed at boosting local production, adding new manufacturing lines, and strengthening export capacity, according to statements from industry leaders carried by reliable regional business media.
Private pharmaceutical companies are planning to inject around EGP 5 billion into Egypt’s drug manufacturing sector during 2026, with investments focused on adding nearly 10 new production lines, according to Gamal El‑Laithy, head of the pharmaceutical chamber at the Federation of Egyptian Industries. The new investments are intended to support import substitution, meet rising domestic demand, and expand exports to regional markets.
El-Laithy, who also chairs Future Pharma, said the company has already begun full operations at its new sterile products plant, a project with an estimated cost of EGP 2.5 billion, reflecting a growing focus on high-value and complex pharmaceutical formulations.
Major listed manufacturers are also advancing capacity expansion plans. Egyptian International Pharmaceutical Industries Company (EIPICO) has completed construction of its new production facility, “EIPICO 3,” with total investments of $100 million, according to chairman Ahmed El‑Kilany. Commercial operations are scheduled to begin in January, adding to the company’s manufacturing footprint.
Meanwhile, Utopia Pharmaceuticals plans to expand its existing factory by investing EGP 600 million during 2026, raising its cumulative investments to nearly EGP 2 billion, according to chairman Saeed Kamel. The expansion is expected to increase output and diversify product lines.
Further reinforcing the sector’s momentum, Memphis Pharmaceuticals is preparing a development programme involving investments exceeding EGP 500 million to modernise production lines and raise manufacturing capacity, according to non-executive chairman Essam Sadek.
Together with rising interest from foreign and regional investors seeking to establish new drug plants in Egypt, the latest private-sector commitments highlight a broader shift toward localisation, higher-value manufacturing, and export-oriented growth, positioning Egypt to consolidate its role as a regional pharmaceutical production hub in the coming years.
